OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Real-time Boerse Frankfurt Warrants 05:55:03 13/06/2024 pm IST | ||
| 0.96 EUR | +3.23% |
|
| Current month | +32.86% | ||
| 1 month | +4.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 13/24/13 | 0.96 | +3.23% |
| 12/24/12 | 0.93 | +6.90% |
| 11/24/11 | 0.87 | -23.01% |
| 10/24/10 | 1.13 | +3.67% |
| 07/24/07 | 1.09 | -6.84% |
Real-time Boerse Frankfurt Warrants
Last update June 13, 2024 at 05:55 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SW9P4E |
| ISIN | DE000SW9P4E8 |
| Date issued | 29/04/2024 |
| Strike | 11,633 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.24 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.01 € |
| Spread % | 1.02% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
160.1
USD
Average target price
174.4
USD
Spread / Average Target
+8.96%
- Stock Market
- Certificates
- Certificat
